Overcoming obstacles to repurposing for neurodegenerative disease.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4184781)

Published in Ann Clin Transl Neurol on June 24, 2014

Authors

Diana W Shineman1, John Alam2, Margaret Anderson3, Sandra E Black4, Aaron J Carman1, Jeffrey L Cummings5, Penny A Dacks1, Joel T Dudley6, Donald E Frail7, Allan Green8, Rachel F Lane1, Debra Lappin9, Tanya Simuni10, Richard G Stefanacci11, Todd Sherer12, Howard M Fillit1

Author Affiliations

1: Alzheimer's Drug Discovery Foundation 57 West 57th Street, Suite 904, New York City, New York, 10019.
2: Eip pharma, LLC 11 Channing Street, Cambridge, Massachusetts, 02183.
3: Faster Cures 1101 New York Ave, NW Suite 620, Washington, District of Columbia, 20005.
4: Sunnybrook Health Sciences Centre, University of Toronto Room A421- 2075, Bayview Avenue, Toronto, Ontario, M4N 3M5.
5: Cleveland Clinic 888 W Bonneville Ave, Las Vegas, Nevada, 89106.
6: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai One Gustave L Levy Pl, New York City, New York, 10029.
7: AstraZeneca 35 Gatehouse Drive, Waltham, Massachusetts, 02451.
8: SDG, LLC One Mifflin Place, Suite 400, Cambridge, Massachusetts, 02138.
9: FaegreBD Consulting 1050 K Street NW, Suite 400, Washington, District of Columbia, 20001.
10: Northwestern University Feinberg School of Medicine 710 North Lake shore Drive, Chicago, Illinois, 60611.
11: The Access Group 400 Connell Drive FL2, Berkeley Heights, New Jersey, 07922.
12: The Michael J. Fox Foundation for Parkinson's Research Grand Central Station, P.O. Box 4777, New York City, New York, 10163-4777.

Associated clinical trials:

Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" Study | NCT03840005